REGULATORY OVERSIGHT OF EARLY-PHASE CLINICAL TRIALS ACROSS KEY AGENCIES

Introduction

Early-phase clinical trials must comply with strict regulatory requirements to ensure patient safety, ethical compliance, and scientific rigor. However, approval pathways, submission processes, and expedited options vary significantly across global regulatory agencies.

This table provides a concise comparison of major regulatory bodies governing early-phase trials, helping biotech and pharma sponsors navigate **approval timelines**, **ethical considerations**, and **fast-track pathways**.

Global Regulatory Comparison for Early-Phase Clinical Trials

Regulatory Authority	Country Region	Key Regulations for Early-Phase Trials	Submission Process	Ethical & Safety Oversight	Expedited Pathways
FDA (Food & Drug Administration)	USA	**21 CFR Part 312 (IND Regulations)** – IND application required before Phase I; robust preclinical safety data essential.	IND submission to FDA; **30-day review period** before trial initiation.	**Institutional Review Board (IRB)** approval; compliance with **ICH-GCP & Common Rule (45 CFR 46).**	**Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review** – supports faster drug access.
EMA (European Medicines Agency)	EU	**EU Clinical Trials Regulation (CTR, EU No 536/2014)** – Harmonized approval process across all 27 EU member states.	**Centralized submission** via **Clinical Trials Information System (CTIS); multi-country approvals** possible in one application.	**Ethics Committee (EC)** review required; **Good Manufacturing Practice (GMP)** compliance mandatory.	**PRIME (Priority Medicines), Adaptive Licensing** – accelerates innovative drug approvals.
PMDA (Pharmaceuticals & Medical Devices Agency)	Japan	**Pharmaceuticals and Medical Devices Act (PMD Act)** – Pre-trial consultation required for Phase I submissions.	**Pre-review consultation required;** IND equivalent submission needed before trials.	**Bioethics Committee** approval mandatory; **risk-based monitoring encouraged.**	**Sakigake Designation** – prioritizes breakthrough drugs for **faster approval**.
TGA (Therapeutic Goods Administration)	Australia	**Clinical Trial Notification (CTN) & Clinical Trial Approval (CTA) schemes** – Sponsor-driven trial approvals.	**CTN:** Sponsor notifies TGA (no review required); **CTA:** Requires TGA evaluation.	**Human Research Ethics Committee (HREC)** approval required; **TGA's risk-based GCP** framework applied.	**Priority Review & Provisional Approval** – shorter approval timelines for critical therapies.

The table continues in the next page

Global Regulatory Comparison for Early-Phase Clinical Trials

Regulatory Authority	Country Region	Key Regulations for Early-Phase Trials	Submission Process	Ethical & Safety Oversight	Expedited Pathways
NMPA (National Medical Products Administration)	China	**Drug Administration Law & Provisions for Drug Registration (2020)** – IND submission required for first-in-human (FIH) trials.	**IND review period: 60 working days** before trial initiation.	**Ethics committee review required; real-world evidence (RWE) encouraged** for approvals.	**Breakthrough Therapy, Conditional Approval** – prioritizes innovative **& biosimilar therapies**.
MFDS (Ministry of Food and Drug Safety)	South Korea	**Pharmaceutical Affairs Act & Clinical Trial Guidelines** – IND submission required before Phase I.	IND submission to MFDS; **approval timeline varies based on trial complexity**.	**Institutional Bioethics Committee review** required; **local site inspections mandatory**.	**Fast-Track & Global Innovative Drug Program** – speeds up **novel drug & biosimilar approvals.**

Key Takeaways from Global Biomarker Regulations in Early-Phase Trials

Harmonization Through ICH Guidelines

Most agencies align with ICH E15 (Definitions for Genomic Biomarkers) and ICH E16 (Qualification of Genomic Biomarkers) to establish global biomarker qualification standards.

Companion Diagnostics (CDx) Requirements

Regulators including FDA, EMA, PMDA, NMPA, and MFDS mandate validated companion diagnostics (CDx) for targeted therapies, ensuring biomarker-based patient selection for precision medicine.

Early Regulatory Engagement Encouraged

- **EMA:** Provides Scientific Advice for biomarker validation.
- **FDA:** Offers Biomarker Qualification Program (BQP) to accelerate biomarker-driven trials.
- **PMDA:** Requires pre-approval consultations for biomarkers in early-phase trials.
- **Oncology & Precision Medicine at the Forefront:** Early-phase oncology trials (e.g., NCI-MATCH, MoST, and basket/umbrella trials) are driving biomarker adoption worldwide, influencing regulatory decision-making across all major agencies.
- **AI & Real-World Data (RWD) Integration:** Regulators in China (NMPA) and South Korea (MFDS) are leading AI-driven biomarker validation efforts, incorporating real-world evidence (RWE) to fast-track approvals.

Final Thoughts: Why Biomarker Regulations Matter for Early-Phase Trials

Biomarker integration is revolutionizing early-phase clinical trials, enabling more **efficient, personalized drug development strategies**. As regulatory agencies continue refining biomarker qualification requirements, sponsors must stay ahead of evolving regulations to accelerate approvals.

Need expert guidance on biomarker-driven regulatory strategies?

Download our White Paper: *Recent Advances in Early-Phase Clinical Trials* for a deeper dive into AI-driven biomarker validation, regulatory pathways, and trial innovations.

Contact Our Experts for a Consultation:
bdglobal@accelsiors.com | +41 41 799 69 40 | LinkedIn